Dr. Reddys Laboratories is currently trading at Rs. 2884.95, up by 13.45 points or 0.47% from its previous closing of Rs. 2871.50 on the BSE.
The scrip opened at Rs. 2868.00 and has touched a high and low of Rs. 2892.00 and Rs. 2853.00 respectively. So far 8352 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 5 has touched a 52 week high of Rs. 2965.20 on 02-May-2019 and a 52 week low of Rs. 2065.30 on 15-Feb-2019.
Last one week high and low of the scrip stood at Rs. 2902.00 and Rs. 2724.15 respectively. The current market cap of the company is Rs. 47868.25 crore.
The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.04% and 14.03% respectively.
Dr. Reddy’s Laboratories has launched Doxercalciferol Injection,4 mcg/2 ml (2 mcg/ml) multiple-dose vials, the therapeutic generic equivalent of Hectorol (doxercalciferol) injection 4 mcg/2 ml (2 mcg/ml) Multiple – Dose Vials, approved by the U.S. Food and Drug Administration (USFDA).
The Hectorol injection 4 mcg/2 ml (2 mcg/ml) single-dose vials and multiple-dose vials brand and generics had U.S. sales of approximately $138 million MAT for the most recent twelve months ending in September 2019 according to IQVIA Health.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharm aceuticals in India and overseas.